The MedTech Forum 2018 – Brussels

Aquarius Population Health is excited to participate in the 2018 MedTech Forum in Brussels on the 23-25th January. The MedTech Forum is one of the largest health and medical technology industry conferences in Europe. Since 2007, it provides participants with the chance to gather insights on the latest industry trends, as well as networking opportunities with other business leaders, leading innovators and investors. The MTF 2018 programme will focus on digital developments, new business strategies and innovation.

Continue reading

Featured

MedTech Forum 2018

Aquarius Population Health is excited to participate in the 2018 MedTech Forum in Brussels on the 23-25th January. The MedTech Forum is one of the largest health and medical technology industry conferences in Europe. Since 2007, it provides participants with the chance to gather insights on the latest industry trends, as well as networking opportunities with other business leaders, leading innovators and investors. The MTF 2018 programme will focus on digital developments, new business strategies and innovation.

At this year’s Forum, Aquarius will be exhibiting along with other innovative MedTech companies and partners. Stop by our stand and have a chat with the team –Elisabeth, Susie and Mike will be on hand to hear about your challenges and come up with creative solutions. We will also be showcasing our interactive decision tools and will have live demos to try out.

We hope to see you there! And if you can’t make it, but still want to see the demo tools, get in touch to set up a meeting.

A rapid testing service for chlamydia and gonorrhoea yields significant patient and public health benefits

Aquarius Population Health, a leading independent health economics consultancy, worked with Chelsea and Westminster NHS Foundation Trust to assess the impact of Dean Street Express, their award winning sexual health clinic in Soho, London. This service tests symptom-free people wanting a routine sexual health check-up using an on-site 90-minute chlamydia and gonorrhoea rapid test. They estimated the patient and public health benefits of their rapid testing service, and compared to the standard sexual health service that didn’t offer rapid delivery of test results.

Continue reading

Digital health, health economics and Zombies!

What do digital health, health economics, making better decisions, and zombies have in common? Much more than you think!

We recently attended the the Digital Art of the Possible 2  (DAP2) event hosted by the West of England Academic Health Science Network (WEAHSN) with our good friend, Charles Lowe, from the Digital Health and Care Alliance .  At the DAP2 event, the future of digital health technology in the NHS was discussed including case studies of what has worked well across the area. Elisabeth said a few words about the importance of digital health technology to businesses and the NHS (video).

Continue reading

Integrating Personalised Medicine into the NHS

Personalised medicine is an emerging field that brings exciting changes to patient care. So, what exactly is personalised medicine and what are its benefits?

In the past, various terms have been used interchangeably: ‘stratified medicine’, ‘personalised medicine’ and ‘precision medicine’. These terms refer to data driven medicine, in which data can be a patient’s genetic makeup, molecular data or disposition to respond to therapy. These data allow for a targeted approach to prevention, diagnosis and treatment using technologies such as genomic medicine, diagnostic tests, predictive data analytics or real-time patient monitoring.

Continue reading

Antimicrobial resistance point-of-care test for gonorrhoea

In a study commissioned by the Review on Antimicrobial Resistance, Aquarius Population Health worked with modellers at the University of Bristol to create a mathematical model. The model was used to assess the economic implications and treatment impact of introducing a hypothetical antimicrobial resistance (AMR) point-of-care test (POCT) for gonorrhoea. Results of the study were published this week in BMJ Open.

Continue reading

Antimicrobial Resistance: Innovation in rapid diagnostics

Part 3: What role does innovation such as rapid diagnostics have in preventing AMR?

Just as new technology has helped us in the fight against global warming (fuel efficiency, clean energy etc.), technology can also help us in the fight against antimicrobial resistance (AMR). One such area is rapid diagnostics – identified as a key intervention for reducing AMR in the government’s 2016 Review of Antimicrobial Resistance.

Continue reading

An intern’s experience at Aquarius Population Health

Ed Collins, Summer Intern
Ed Collins, Summer Intern

When I started hunting for internships towards the end of the third year of my Computer Science degree, I knew that I wanted to work for a small and growing business. I found Aquarius through the UCL Advances internship scheme that specialises in small to medium sized businesses. Aquarius offered the perfect combination of experiences for me: a way to apply my technical skills while being exposed to the fundamentals of how a growing business was run. My primary task was building an online data portal that the team could use to store and organise their data related to their various projects.

Continue reading

Point of care testing: Disruptive innovation – is the NHS ready for it yet?

Elisabeth AdamsOur Managing Director, Elisabeth Adams, spoke in November about the importance of exploring the health economics of point of care testing (POCT) at the Royal Society of Medicine Telemedicine and eHealth event in London. The video of her presentation is now online – view the full talk here.

Why is it important to explore the health economics of point of care testing (POCT)?

Evaluating the health economics of POCTs can help us better understand the cost, benefits and value of implementing these tests, compared to standard laboratory tests. We need to explore the acquisition costs of innovative technology like POCTs compared to standard tests, as well as the benefits generated for patients, service providers, clinicians and public health in general. Benefits can include faster results, better care, fewer complications, more efficient services and better use of resources, and knock-on benefits like reduced prevalence of disease. Those making purchasing decisions for new tests need evidence to prove the value of the tests.

Continue reading